1. Home
  2. ALXO vs VATE Comparison

ALXO vs VATE Comparison

Compare ALXO & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.08

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$4.22

Market Cap

74.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALXO
VATE
Founded
2015
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
68.3M
74.0M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
ALXO
VATE
Price
$2.08
$4.22
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
717.0K
13.6K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
26.36
N/A
EPS
N/A
N/A
Revenue
N/A
$1,107,100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$4.04
52 Week High
$2.66
$9.01

Technical Indicators

Market Signals
Indicator
ALXO
VATE
Relative Strength Index (RSI) 50.48 29.02
Support Level $2.01 $4.11
Resistance Level $2.31 $5.37
Average True Range (ATR) 0.18 0.27
MACD -0.05 -0.08
Stochastic Oscillator 22.31 14.14

Price Performance

Historical Comparison
ALXO
VATE

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.

Share on Social Networks: